Kyverna Therapeutics, Inc. (KYTX)

Kyverna Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-160.99	-127.48	-60.37	-28.89	-26.35
Depreciation & Amortization	1.99	2.13	1.71	1.05	0.59
Stock-Based Compensation	8.76	8.36	2.22	0.93	0.25
Other Adjustments	-3.95	-5.12	0.61	1.13	7.85
Changes in Accounts Payable	-6.91	0.74	4.08	0.68	0.01
Changes in Accrued Expenses	9.99	12.98	4.06	-1.37	2.53
Changes in Unearned Revenue	-	-	-	-7.03	-5.66
Changes in Other Operating Activities	-5.57	-5.86	-4.72	-2.61	-1.37
Operating Cash Flow	-157.25	-114.25	-52.41	-36.11	-22.16
Capital Expenditures	-0.54	-2.21	-0.62	-0.77	-1.29
Purchases of Intangible Assets	-0.49	-	-	-	-
Purchases of Investments	-375.92	-490	-54.85	-56.5	-
Proceeds from Sale of Investments	463.5	331.3	46.68	43.17	-
Investing Cash Flow	86.52	-160.9	-8.79	-14.1	-1.29
Issuance of Common Stock	1.69	341.43	0.65	0.18	0.03
Repurchase of Common Stock	-0.07	-	-	-	-
Net Common Stock Issued (Repurchased)	1.62	341.43	0.65	0.18	0.03
Issuance of Preferred Stock	-	-	59.9	11.95	72.53
Net Preferred Stock Issued (Repurchased)	-	-	59.9	11.95	72.53
Other Financing Activities	-1.38	-4.32	-2.43	-0.25	-0.04
Financing Cash Flow	0.21	337.11	58.12	11.88	72.52
Net Cash Flow	-70.51	61.96	-3.08	-38.33	49.08
Free Cash Flow	-157.78	-116.46	-53.03	-36.88	-23.44
FCF Margin	-	-	-	-525.00%	-414.50%
Free Cash Flow Per Share	-3.65	-3.04	-78.73	-80.97	-0.09
Levered Free Cash Flow	-162.02	-119.69	-55.86	-38.94	-31.54
Unlevered Free Cash Flow	-172.61	-134.82	-57.9	-39.43	-31.54

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q